+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center



De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center



Leukemia & Lymphoma 47(8): 1557-1564



We retrospectively studied the outcomes of adults with de novo acute myeloid leukemia treated in a reference center in Brazil and analyzed the association with the human development index (HDI) of the United Nations used as a socioeconomic factor. Among 123 patients, 46 (37%) died during induction, 65 (53%) reached complete remission and 45 (37%) received high-dose cytarabine (Hidac) consolidation. The 5-year overall survival and leukemia-free survival (LFS) were 17 and 26%, respectively, for all patients and 36 and 30%, respectively, for those receiving Hidac. In multivariate analysis, an HDI <0.660 was associated with a lower probability to receive Hidac (P = 0.001), a trend for higher mortality in remission induction (P = 0.062) and a decreased LFS (P < 0.0001). However, it was not associated with outcomes for patients receiving Hidac. In conclusion, survival for patients who received Hidac consolidation is satisfactory; however, socioeconomic factors may have selected patients to receive intensive Hidac consolidation.

(PDF emailed within 0-6 h: $19.90)

Accession: 048717510

Download citation: RISBibTeXText

PMID: 16966267

DOI: 10.1080/10428190600627055


Related references

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology 22(21): 4290-4301, 2004

Cytogenetic studies in secondary leukemia Report of 28 cases from one center and comparison with the results in de novo acute myeloid leukemia. Leukemia Research 21(SUPPL 1): S33, 1997

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. Journal of Clinical Oncology 32(3): 219-228, 2014

Cytogenetic and morphological analysis of de novo acute myeloid leukemia in adults: a single center study in jordan. Balkan Journal of Medical Genetics 15(1): 5-10, 2012

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120(7): 1010-1017, 2014

Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades. Brazilian Journal of Medical and Biological Research 44(7): 660-665, 2012

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. International Journal of Oncology 21(5): 1041-1051, 2002

Treatment of acute myeloid leukemia younger adults: the GOELAM experience. Annals of Hematology 83 Suppl 1: S104-S105, 2004

Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leukemia Research 38(8): 901-906, 2014

Outcomes of younger than 60 years old adults with Ph/BCR-ABL positive acute lymphoblastic leukemia: a single center clinical trial of BDH ALL 2000/02. Zhonghua Xue Ye Xue Za Zhi 34(6): 493-497, 2014

Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 89(7): 791-800, 2004

Feasibility and Results of Autologous Stem Cell Trasplant in De Novo Acute Myeloid Leukemia in Patients over 60 Years Old Interim Results of the CETLAM99 Protocol. Blood 100(11): Abstract No 3393, November 16, 2002

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. American Journal of Hematology 89(11): E193-E199, 2014

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90(12): 4710-4718, 1998